ANNUAL REVIEW OF THE Special Compulsory Licensing System

Report to the General Council

Corrigendum

Annex 1 and Appendix 1 are updated to include the statement made by the European Union.

ANNEX 1

[Excerpt from the Minutes of the Council's meeting of 15-16 october 2020 to be circulated as document IP/C/M/96]

7      Annual review of the Special Compulsory Licensing System (Paragraph 7 of the annex to the amended trips agreement and paragraph 8 of the decision on the implementation of paragraph 6 of the doha declaration on the TRIPS Agreement and Public Health)

7.  The representatives of the WTO Secretariat, Chad (on behalf of the LDC Group), Ukraine, South Africa, India, China, Tanzania (on behalf of the African Group), Japan, Australia, the United States of America, Canada, Chile, and Switzerland took the floor.

_______________

Appendix 1

[Excerpt from the Addendum to the Minutes, containing the statements made during the Council's meeting held on 15-16 october 2020, to be circulated as document IP/C/M/96/Add.1]

Agenda item 7: Annual review of the Special Compulsory Licensing System (Paragraph 7 of the annex to the amended trips agreement and paragraph 8 of the decision on the implementation of paragraph 6 of the doha declaration on the TRIPS Agreement and Public Health)

7.15 European Union

83.  I will just like to thank the Secretariat for the presentation on the system of compulsory licensing and, of course, for the report that we fully support, and congratulate all the Members that have accepted the Protocol since the last review.

84.  The EU has consistently supported the use were necessary and justified of the flexibilities provided under the TRIPS Agreement and in line with the Doha Declaration and with the objective of ensuring access to medicines. We find this mechanism very important and key for ensuring access. I will come back to this issue in more detail under agenda item 15.

__________